Truist Securities initiated coverage of AxoGen, Inc. (NASDAQ: AXGN) with a buy recommendation and a price target of $60 per share, underscoring the company’s position in the high-growth peripheral nerve repair market.
The firm highlighted AxoGen’s strong operational momentum, noting revenue increased 24% year-over-year in the trailing twelve months. In the second quarter of 2026, the company reported total revenue of $69.7 million, a 23% year-over-year rise that surpassed Wall Street’s estimate of $67.1 million. Adjusted earnings per share matched analyst expectations at $0.12, while GAAP net loss narrowed to $1.5 million, or $0.03 per share.
Truist estimated the total addressable market for AxoGen’s products at approximately $5 billion, describing it as largely untapped. The firm projected AxoGen’s revenue growth to exceed 20% annually through 2029, driven by accelerating adoption of its flagship biologic nerve graft, Avance—the first and only biological nerve allograft in its segment—as well as an expanding sales force and productivity gains. Urology and breast reconstruction were identified as key growth areas.
AxoGen’s shares have outperformed peers by 238% over the past twelve months, contrasting with a 10% decline in the IHI index during the same period. The company’s market capitalization stands at $2.68 billion. Truist also noted an expected inflection in profitability and improved free cash flow, though InvestingPro data indicated shares are trading above fair value even as net income is projected to rise this year.
Other analysts have also revised their targets upward: H.C. Wainwright set a $53 price target and Citizens adjusted its target to $55.
